Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Bitcoin ETF (BITO) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

ProShares Bitcoin ETFTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

ProShares Bitcoin ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? ProShares Bitcoin ETF trades at $8.59, while Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M). The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITODNA
Sector
Crypto-linkedHealth
52-Week High
$22.27$16.14
52-Week Low
$7.98$5.48
Market Cap
$515.15M
Enterprise Value
$617.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Bitcoin ETF

BITO trades at $8.79, up 1.03% with a bullish technical signal from moving averages. The ETF maintains a consistent dividend distribution pattern with recent $0.01 payouts. Technical indicators show neutral oscillators but overall positive momentum, with support and resistance clustered around $9. The fund's performance reflects ongoing investor interest in Bitcoin exposure vehicles despite market volatility.

BITO faces structural challenges with higher fees impacting long-term returns compared to spot Bitcoin ETFs. Recent analyst coverage highlights tactical utility but questions buy-and-hold suitability. The fund's correlation breakdown with high-beta equities and persistent crypto market headwinds present significant risk factors for investors seeking sustained growth.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Bitcoin ETF

BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.

Read more on BITO

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA